Core Viewpoint - The change of controlling shareholder to Hainan Yayi is expected to bring potential turnaround opportunities for Sairong Pharmaceutical, which has been under performance pressure and faced risks of delisting due to insufficient R&D investment [1][4]. Group 1: Shareholder Change - Sairong Pharmaceutical announced that its controlling shareholder has changed to Hainan Yayi, which currently has no actual controller, resulting in the company having no actual controller [2][3]. - The transfer of 14.16% of shares from previous controllers Cai Nanguai and Tang Lin to Hainan Yayi was completed at a price of 8 yuan per share, totaling 199 million yuan [1][2]. Group 2: Financial Performance - Sairong Pharmaceutical has faced continuous financial pressure, with only one profitable year since 2020. Revenue figures from 2020 to 2024 were 121 million yuan, 247 million yuan, 264 million yuan, 311 million yuan, and 264 million yuan, while net profits were -67.22 million yuan, -23.34 million yuan, -37.31 million yuan, 9.534 million yuan, and -33.1456 million yuan respectively [4][5]. - The first quarter of 2025 showed a revenue of 54.09 million yuan, a year-on-year decline of 22.2%, and a net loss of 1.04 million yuan, a year-on-year decline of 163.9% [4]. Group 3: Performance Adjustments - Sairong Pharmaceutical has repeatedly revised its performance forecasts from 2021 to 2024, with significant adjustments made to previously reported revenues and profits due to unrecognized income and increased impairment losses [5][6]. - The company was placed under delisting risk warning by the Shenzhen Stock Exchange due to negative profit indicators and revenue below 300 million yuan [6]. Group 4: R&D and Market Position - The company has been criticized for low R&D spending, with 2023 R&D expenses at 27.52 million yuan, only 8.8% of total revenue, below the industry average of 10%-15% [8]. - Sairong Pharmaceutical has won bids for seven products in national procurement, but the drastic price reductions have limited profit margins, leading to a situation where "price for volume" strategy has not compensated for profit losses [8][9]. Group 5: Future Outlook - The company is exploring new growth opportunities, including a newly certified skin care product, but faces challenges in experience and funding [9]. - Sairong Pharmaceutical's management is working closely with new shareholders to improve operational efficiency and business performance, aiming to reverse the current downturn [9].

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-038 赛隆药业集团股份有限公司 关于子公司获得吡拉西坦注射液药品注册证书 的公告 药品注册标准编号：YBH15862025 药品批准文号：国药准字 H20254789/国药准字 H20254788 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 注册分类：化学药品 3 类 赛隆药业集团股份有限公司（以下简称"公司"）全资子公司湖南赛隆药业 （长沙）有限公司于近日获得国家药品监督管理局核准签发的吡拉西坦注射液 《药品注册证书》，现将相关情况公告如下： 证书编号：2025S02101/2025S02100 一、药品基本信息 药品名称：吡拉西坦注射液 剂型：注射剂 规格：5ml：1g/15ml：3g 三、风险提示 上述药品的获批进一步丰富了公司的制剂品种，具体销售情况则取决于内外 部环境变化等多种因素，存在一定的不确定性，公司将及时根据后续进展履行信 息披露义务，敬请广大投资者谨慎决策，注意防范投资风险。 特此公告！ 赛隆药业集团股份有限公司 药品批准文号有效期：至 2030 年 07 月 07 ...

Core Viewpoint - The announcement details the completion of the transfer of 14.16% of the shares of Sairong Pharmaceutical Group Co., Ltd. from its former controlling shareholders to Hainan Yayi, resulting in a change of control of the company [1][2][3]. Group 1: Share Transfer Details - The share transfer involved 24,912,205 shares at a price of 8 RMB per share, totaling 199,297,640 RMB [2][4]. - Following the transfer, Hainan Yayi will hold 24.60% of the voting rights in the company, establishing it as the new controlling shareholder [3][6]. Group 2: Control Changes - After the transfer, the former controlling shareholders, Cai Nanguai and Tang Lin, will hold 42.46% of the shares but will relinquish all voting rights except for the rights to dividends and share disposal [2][6]. - The company will now be classified as having no actual controller since Hainan Yayi currently has no actual controlling party [3][6]. Group 3: Compliance and Commitments - Hainan Yayi has committed not to transfer or delegate management of its shares for 18 months following the completion of the transfer [8]. - The share transfer complies with relevant laws and regulations, ensuring no adverse effects on the company's operations or minority shareholders [8].

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-037 赛隆药业集团股份有限公司 关于控股股东、实际控制人协议转让股份过户完成 暨公司控制权发生变更的公告 根据蔡南桂先生、唐霖女士签署的《关于放弃表决权的承诺函》，自标的股 份过户完成之日起，蔡南桂先生、唐霖女士将无条件且不可撤销地放弃行使其持 有的公司剩余股份所对应的除收益权和股票处置权之外的全部股东权利。因此， 公司的控股股东已变更为海南雅亿，由于目前海南雅亿无实际控制人，故公司无 实际控制人。具体情况如下： 一、本次协议转让的基本情况 2025 年 5 月 18 日，公司控股股东、实际控制人蔡南桂先生、唐霖女士与海 南雅亿签订了《关于赛隆药业集团股份有限公司之股份转让协议》（以下简称"《股 份转让协议》"），蔡南桂先生、唐霖女士合计向海南雅亿转让其持有的公司股 份 24,912,205 股，占公司总股本的 14.16%。本次股份转让价格为 8 元/股，转 让价款合计为人民币 199,297,640.00 元。 此外，蔡南桂先生、唐霖女士就本次股份协议转让签署了《关于放弃表决权 的承诺函》，蔡南桂先生、唐霖女士承诺自本次协议转让股份过户 ...

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-036 赛隆药业集团股份有限公司 关于子公司获得托拉塞米注射液药品注册证书 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）全资子公司湖南赛隆药业 （长沙）有限公司于近日获得国家药品监督管理局核准签发的托拉塞米注射液 《药品注册证书》，现将相关情况公告如下： 一、药品基本信息 药品名称：托拉塞米注射液 剂型：注射剂 药品批准文号有效期：至 2030 年 06 月 29 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 二、药品其他相关信息 托拉塞米注射液为《国家基本医疗保险、工伤保险和生育保险药品目录（2024 年）》乙类药品，适用于需要迅速利尿或不能口服利尿剂的充血性心力衰竭、肝 硬化腹水、肾脏疾病所致的水肿患者。 规格：2ml：10mg/4ml：20mg 注册 ...

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].

1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）股票（证 券简称：*ST 赛隆，证券代码：002898）于 2025 年 6 月 19 日、6 月 20 日、6 月 23 日连续 3 个交易日收盘价格累计偏离-12.66%，根据深圳证券交易所有关规定， 属于股票交易异常波动的情况。 2.截至本公告披露时，中证指数有限公司的最新数据显示，公司的静态市盈 率为-63.88，市净率为 4.25。公司所属中上协行业分类"C27 医药制造业"的静 态市盈率为 27.97，市净率为 2.73。公司静态市盈率和市净率与同行业的情况有 较大差异，公司特别提醒投资者，注意投资风险，理性决策，审慎投资。 3.公司于 2025 年 4 月 25 日披露了《2024 年年度报告》，经审计的年度报 告数据显示，公司 2024 年度利润总额、净利润、扣除非经常性损益后的净利润 三者均为负值，且扣除后的营业收入低于 3 亿元。根据《深圳证券交易所股票上 市规则》第 9.3.1 条规定，公司股票交易于 2025 年 4 月 28 日被深圳证券交易所 实施退市风险警示。若公司 2025 年度出现《深圳证券交易所股票上市规则》第 9 ...

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-034 赛隆药业集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示 1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）股票（证 券简称：*ST 赛隆，证券代码：002898）于 2025 年 6 月 13 日、6 月 16 日、6 月 17 日连续 3 个交易日收盘价格涨幅累计偏离 13.21%，根据深圳证券交易所有关 规定，属于股票交易异常波动的情况。 2.截至本公告披露时，中证指数有限公司的最新数据显示，公司的静态市盈 率为-72.85，市净率为 4.84。公司所属中上协行业分类"C27 医药制造业"的静 态市盈率为 29.11，市净率为 2.85。公司静态市盈率和市净率与同行业的情况有 较大差异，公司特别提醒投资者，注意投资风险，理性决策，审慎投资。 3.近期公司股价短期涨幅较大，明显偏离市场走势，存在市场情绪过热的风 险。但公司基本面没有重大变化，也不存在应披露而未披露的重大信息。公司已 发布多次股票交易异常波动公告及一次股票交易严重异常波动公告， ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

Policy Developments - The National Health Commission of China is taking measures to ensure blood supply in key areas and important time periods due to a noticeable decline in voluntary blood donations, influenced by factors such as aging population and lifestyle changes [2] - In 2024, the total blood supply in China is expected to decrease year-on-year, with a cumulative blood allocation of 3.613 million units, including 583,000 units allocated between provinces, representing a 35.1% increase [2] Drug and Medical Device Approvals - Kelun Pharmaceutical announced that its subsidiary has received drug registration approval for "Cefazolin Sodium/ Sodium Chloride Injection," which is packaged in a dual-chamber bag and is suitable for emergency treatment [4] - *ST Sailong's subsidiary has obtained a drug registration certificate for Famotidine Injection, classified as a Category A drug under the national medical insurance list, primarily used for treating upper gastrointestinal bleeding [5] Capital Market Activities - Borui Pharmaceutical plans to invest 20 million yuan to subscribe to the increased registered capital of Geek Gene Technology, acquiring a 4.1667% stake in the company [7] Industry Developments - Eli Lilly announced the launch of the multi-dose prefilled pen for Tirzepatide Injection in China, aimed at addressing the needs of the growing number of diabetes and obesity patients [9] - The adult overweight rate in China is 34.3%, with an obesity rate of 16.4%, highlighting the increasing demand for weight management treatments [9] - In the first quarter of this year, Tirzepatide contributed $6.15 billion in revenue to Eli Lilly, accounting for approximately 48% of the company's total revenue [10] - Hanyu Pharmaceutical has completed the enrollment of all subjects for the Phase III clinical trial of Semaglutide Injection for weight management, currently in the follow-up phase [11] Shareholder Actions - Nine Strong Bio's major shareholder completed a share reduction plan, reducing their holdings from 30,969,636 shares to 30,769,636 shares, a decrease from 5.30% to 5.26% of voting shares [13] - Yifeng Pharmacy's controlling shareholder plans to reduce their stake by up to 2%, amounting to no more than 24,248,336 shares [14]